|Bid||1,452.00 x 0|
|Ask||1,454.00 x 0|
|Day's range||1,430.00 - 1,540.00|
|52-week range||774.33 - 1,554.20|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
Oxford Biomedica is doubling the volume of Covid vaccine it is making for AstraZeneca on the back of soaring demand for the jab. The biotech is one of two companies in the UK that manufactures the jab for AstraZeneca and is the pharmaceutical giant's biggest domestic supplier. John Dawson, chief executive of Oxford Biomedica, said production volumes would double by the end of the year to meet increased demand after the two companies revised their supply agreement. AstraZeneca would not confirm if the additional doses were being made for the domestic market or exported. The company said the extra supply was due to higher demand rather than manufacturing constraints elsewhere. The increase is a boon for Oxford Biomedica, which will see its vaccine sales rise from £50m to £100m by the end of the year and significantly boost profits. The news sent shares in the company up by more than 13pc.
The company has said a new deal with AstraZeneca to manufacture the vaccine will also see revenues jump from £50 million to £100 million.